ACTA1 and cardiac hypertrophy: Blocking of TGF-β/SMAD4 pathway, with reduced α-SMA levels, cardiac inflammation and macrophage infiltration. Reduced calcineurin expression and MAPK activation, attenuating cardiac hypertrophy.